Synagis Drug Interactions

No formal drug-drug interaction studies were conducted; however, no interactions have been described to date. In the phase III IMpact-RSV study, the proportions of patients in the placebo and SYNAGIS groups who received routine childhood vaccines, influenza vaccine, bronchodilators or corticosteroids were similar and no incremental increase in adverse reactions was observed among patients receiving these agents, in either of the two groups.
Since the monoclonal antibody is specific for RSV, SYNAGIS is not expected to interfere with the immune response to vaccines, including live viral vaccines.
Drug/Laboratory Test Interaction: Palivizumab may interfere with immune-based RSV diagnostic tests, such as some antigen detection-based assays. In addition, palivizumab inhibits virus replication in cell culture and therefore may also interfere with viral culture assays. Palivizumab does not interfere with reverse transcriptase polymerase chain reaction-based assays. Assay interference could lead to false-negative RSV diagnostic test results. Therefore, diagnostic test results, when obtained, should be used in conjunction with clinical findings to guide medical decisions.